Nasdaq apls.

WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and ...Apr 24, 2023 · The forecasts range from a low of 51.51 to a high of $148.05. The average price target represents a decrease of 4.25% from its latest reported closing price of 93.18. See our leaderboard of ... Dec 4, 2023 · Apellis Pharmaceuticals Stock Down 1.9 %. Shares of NASDAQ:APLS opened at $60.40 on Monday. The company’s fifty day moving average price is $46.23 and its 200 day moving average price is $55.22. View live Apellis Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, APLS financials and market news.WALTHAM, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from ...

WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing ...Analyst's Opinion · Consensus Rating. Apellis Pharmaceuticals has received a consensus rating of Moderate Buy. · Price Target Upside/Downside. According to ...Dec 1, 2023 · 14 analysts have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's share price to reach $66.50 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price.

Nov 17, 2023 · Apellis Pharmaceuticals Inc (Symbol: APLS) saw options trading volume of 11,658 contracts, representing approximately 1.2 million underlying shares or approximately 61.6% of APLS's average daily ...

Find the latest Institutional Holdings data for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.APLS Real-Time Quotes. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and ...APLS is trading at a 30% discount. Price $53.92. Nov 30, 2023. Fair Value $86.12. Nov 30, 2023 ... Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)3 дня назад ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.

Apellis Pharmaceuticals (NASDAQ:APLS) has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026.; Under the terms of ...

For instance, the price of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stock is up an impressive 177% over the last five years. It's also good to see the share price up 19% over the last quarter.

Bluebird bio Inc (NASDAQ:BLUE) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. ... (NASDAQ:APLS) (after the close)Apellis Pharmaceuticals (NASDAQ: APLS) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts.. Apellis Pharmaceuticals has announced that it ...APLS Quantitative Stock Analysis. June 27, 2023 — 12:04 pm EDT. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for APELLIS PHARMACEUTICALS INC ( APLS). Of the ...WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has ...APLS Earnings Date and Information. Apellis Pharmaceuticals last released its quarterly earnings data on November 1st, 2023. The reported ($1.17) EPS for the …Bluebird bio Inc (NASDAQ:BLUE) was among the worst performers of the week after the company temporarily stalled its gene therapy studies in sickle cell disease. ... (NASDAQ:APLS) (after the close)

The public float for APLS is 97.66M, and at present, short sellers hold a 16.62% of that float. On November 16, 2023, the average trading volume of APLS was 2.69M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 0.54relation to previous closing price of 48.14.WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on ...The latest price target for Apellis Pharmaceuticals ( NASDAQ: APLS) was reported by Goldman Sachs on Thursday, November 9, 2023. The analyst firm set a price target for 74.00 expecting APLS to ...Reported EPS is $-1.17 EPS, expectations were $-0.86. Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings ...The public float for APLS is 96.80M and currently, short sellers hold a 16.67% of that float. On November 29, 2023, APLS’s average trading volume was 2.29M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 5.56relation to previous closing price of 47.16.WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved ...On today's stock market, APLS stock plummeted 37.9% to 52.46. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.

WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its first ...Follow. WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that four oral ...

WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its ...WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its third quarter 2021 ...Wall Street Analysts Predict a 51.91% Upside in Apellis Pharmaceuticals, Inc. (APLS): Here's What You Should Know. (Zacks) Oct-25-23 07:00AM. Apellis …WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ...23 de ago. de 2023 ... Apellis Pharmaceuticals Inc (NASDAQ:APLS) jumped some 35% in Wednesday's deals after last night updating investors on an ongoing safety ...APLS technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Apellis Pharmaceuticals, Inc. is based on the …Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. …How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold.View live Apellis Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, APLS financials and market news.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) on December 1 and set a price target of $70.00. Yigal Nochomovitz’s Buy rating for ...

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...

Apellis Pharmaceuticals, Inc. (APLS). NASDAQ: APLS · IEX Real-Time Price · USD.WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ...WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ...WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved ...Nov 19, 2023 · Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin ... The public float for APLS is 96.80M and currently, short sellers hold a 16.67% of that float. On November 29, 2023, APLS’s average trading volume was 2.29M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 5.56relation to previous closing price of 47.16.WALTHAM, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...Nov 29, 2023 · Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information. Instantly APLS has showed a red trend with a performance of -2.34% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 50.19 on Tuesday, 11/28/23 increased the stock’s daily price by 6.04%.

WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...Jul 6, 2023 · Fintel reports that on July 21, 2023, HC Wainwright & Co. maintained coverage of Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy recommendation. Analyst Price Forecast Suggests 203.86% Upside. As ... Apellis Pharmaceuticals Stock Up 14.3 %. APLS stock traded up $7.71 during midday trading on Friday, hitting $61.58. The company’s stock had a trading volume of 5,431,264 shares, compared to its ...Instagram:https://instagram. female financial advisor2009 penniesget funded to trade optionsdental insurance maryland WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ... indhotelbest bullion dealer Apellis Pharmaceuticals, Inc. APLS reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65. The loss was also narrower than our ...(APLS) Share Price. NASDAQ. $49.10. As on 17-Nov-2023 16:00 EST. up-down-arrow $1.21 • 2.53%. Prev Close info. $47.89. Day's Open info. $47.74. Today's High ... best budgeting apps for teens WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its ...Apellis Pharmaceuticals Inc (Symbol: APLS) saw options trading volume of 11,658 contracts, representing approximately 1.2 million underlying shares or approximately 61.6% of APLS's average daily ...